PDRN Safety and Immunogenicity Profile: Comprehensive Review of Clinical and Preclinical Data (2022)

Key Findings

• Across 20+ years of clinical use and multiple clinical trials, no significant immunogenic or allergic reactions have been attributed to pharmaceutical-grade PDRN administered via intradermal injection, intramuscular injection, or topical application ^[1][2][3].
• The purification process eliminates proteins and peptides — the molecular classes responsible for virtually all allergic reactions — from the final PDRN product, leaving only purified DNA fragments with no detectable proteinaceous content ^[2][6].
• Preclinical mutagenicity testing (Ames test, in vivo micronucleus assay) has demonstrated no mutagenic or genotoxic activity from PDRN administration ^[2].
• Fish allergy, the most commonly raised patient concern, is mediated by the protein parvalbumin — which is absent from purified PDRN. Patients with fish allergy are not at elevated risk from PDRN use ^[1][2].

Abstract

This comprehensive review evaluates the safety and immunogenicity profile of polydeoxyribonucleotide (PDRN) by synthesizing data from clinical trials, post-market surveillance, preclinical toxicology studies, and pharmacovigilance records accumulated over more than two decades of medical use ^[1][2][3]. PDRN, a purified DNA fragment extracted from the sperm cells of Oncorhynchus keta (chum salmon), has been used clinically as an injectable tissue repair agent since the early 2000s, with applications expanding into aesthetic dermatology (skin boosters, mesotherapy) and topical skincare in recent years ^[1][3]. As consumer and practitioner exposure to PDRN increases rapidly, a consolidated understanding of its safety profile is essential. The review addresses four primary safety domains: (1) immunogenicity and allergic potential, (2) systemic toxicity, (3) mutagenicity and genotoxicity, and (4) local tolerability across different routes of administration ^[1][2].

Immunogenicity and Allergic Potential

The immunogenicity of an exogenous biological material — its capacity to provoke an immune response — is determined primarily by its molecular composition, particularly the presence of proteins and glycoproteins that can be recognized as foreign antigens ^[1][2]. PDRN's safety in this domain rests on a critical physical chemistry property: the manufacturing process subjects salmon sperm cell extracts to high-temperature deproteinization, enzymatic digestion, and multi-step chromatographic purification that eliminates proteins, peptides, and lipopolysaccharides from the final product ^[2][6]. The resulting material is >95% pure polydeoxyribonucleotide with no detectable protein content ^[2][6].

DNA itself is a poor immunogen in mammalian systems ^[1][2]. Double-stranded DNA from vertebrate sources does not effectively activate Toll-like receptor 9 (TLR9) — the innate immune sensor for unmethylated CpG motifs that is primarily responsive to bacterial and viral DNA — because vertebrate DNA is extensively methylated at CpG dinucleotides ^[1][2]. PDRN, being derived from a vertebrate species (salmon), carries the methylation pattern characteristic of vertebrate genomes, rendering it immunologically inert with respect to TLR9-mediated immune activation ^[1][2].

Clinical data from multiple randomized controlled trials involving intradermal injection of PDRN — a more immunologically provocative route than topical application — report no cases of allergic reaction, anaphylaxis, antibody formation, or hypersensitivity reactions attributable to PDRN ^[1][3][4][5]. Post-market surveillance data from Italy and South Korea, where PDRN injectables have the longest commercial history, corroborate this finding ^[1][2].

Fish allergy and PDRN

The most frequently asked safety question regarding PDRN is whether patients with fish allergy are at risk ^[1][2]. The answer is no, for a specific biochemical reason: fish allergy is mediated by IgE antibodies directed against parvalbumin, a calcium-binding protein found in fish muscle tissue ^[1][2]. Parvalbumin is a protein — it is completely absent from purified PDRN, which contains only DNA fragments ^[2][6]. The salmon sperm cells from which PDRN is extracted are not muscle tissue, and even the crude starting material does not contain significant parvalbumin. After the multi-step purification process, no protein of any kind remains at detectable levels ^[2][6].

Nevertheless, as with any biological-derived product, practitioners exercising maximal caution may elect to perform a small test injection in patients with severe fish allergy, particularly for injectable PDRN products. For topical PDRN skincare, the risk is negligible ^[1][2].

Systemic Toxicity

Preclinical toxicology studies in animal models (rats and rabbits) have evaluated PDRN safety across acute, sub-chronic, and chronic exposure protocols ^[2]:

• Acute toxicity: Single-dose studies at suprapharmacological doses showed no mortality, organ damage, or behavioral abnormalities ^[2].
• Sub-chronic toxicity (28-day repeated dose): Daily PDRN administration at multiples of the clinical dose produced no hematological, biochemical, or histopathological abnormalities in any organ system examined (liver, kidney, spleen, heart, lung, brain) ^[2].
• Reproductive toxicity: No teratogenic or embryotoxic effects were observed in standard reproductive toxicity protocols, consistent with the biologically inert nature of short DNA fragments ^[2].

In clinical use, PDRN is administered at relatively low total doses (5.625 mg per injection session for dermal skin boosters) that are rapidly metabolized through endogenous nuclease activity ^[1][2]. The degradation products — individual nucleotides and nucleosides — enter the normal purine and pyrimidine salvage and degradation pathways, producing no novel metabolites ^[1][2].

Mutagenicity and Genotoxicity

The administration of exogenous DNA fragments raises a theoretical question about integration into the host genome ^[2]. PDRN has been tested with the standard battery of genotoxicity assays required by regulatory agencies ^[2]:

• Ames test (bacterial reverse mutation assay): Negative — PDRN did not induce mutations in five Salmonella typhimurium strains, with or without metabolic activation ^[2].
• In vitro chromosomal aberration assay: Negative — no increase in chromosomal damage in cultured mammalian cells ^[2].
• In vivo micronucleus assay: Negative — no increase in micronucleated erythrocytes in bone marrow of treated animals ^[2].

The biological rationale for the negative genotoxicity profile is straightforward: PDRN fragments (50-1500 kDa) are too large to enter the nucleus intact and too short and random in sequence to serve as substrates for homologous recombination ^[1][2]. They are rapidly degraded by extracellular and intracellular nucleases into individual nucleotides that enter normal metabolic pathways ^[1][2].

Local Tolerability

Injectable administration

Intradermal and intramuscular PDRN injections are well-tolerated ^[1][3][4]. The most commonly reported adverse events in clinical trials are:

• Injection site pain: Mild, transient, comparable to saline injection. Related to the injection procedure itself rather than PDRN ^[3][4].
• Injection site bruising: Occasional, related to needle trauma. Resolves spontaneously in 3-7 days ^[4].
• Injection site erythema: Mild, transient redness lasting 1-24 hours post-injection ^[3][4].

No cases of injection site granuloma, nodule formation, necrosis, or infection attributable to PDRN have been reported in the clinical literature ^[1][3][4].

Topical application

Topical PDRN products (serums, creams, ampoules, masks) have the most benign tolerability profile of all administration routes ^[1][2][3]. Clinical and consumer reports indicate:

• No irritation, stinging, or burning ^[1][3]
• No contact sensitization or allergic contact dermatitis ^[2]
• No photosensitivity ^[1]
• No comedogenic effects ^[3]
• Suitable for use on post-procedure skin, sensitive skin, rosacea-prone skin, and periorbital skin ^[1][3][4]

Conclusion

The cumulative safety evidence for pharmaceutical-grade PDRN across more than two decades of clinical use and multiple administration routes supports a classification as a low-risk biological material with an excellent tolerability profile ^[1][2][3]. The purification process eliminates the protein content responsible for immunogenic and allergic reactions, vertebrate-methylated DNA does not activate innate immune sensors, and the degradation products are normal endogenous metabolites ^[1][2]. The safety profile is consistent across injectable and topical routes of administration, supporting the ongoing expansion of PDRN applications in both medical and cosmetic dermatology ^[1][3][4]. Patients with fish allergy can use PDRN products without elevated risk, as the allergenic protein parvalbumin is absent from the purified product ^[1][2][6]. Mutagenicity testing has confirmed the expected absence of genotoxic potential ^[2]. For clinicians and consumers, the available data support confidence in the safety of well-manufactured, pharmaceutical-grade PDRN products.